Vimarsana
Biggest News Aggregation in the World

Page 46 - Pharma Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pharma Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pharma Inc Today - Breaking & Trending Today

Silo Pharma Collaborates With Medspray Pharma For Intranasal Technology For Stress Disorder Candidate - SILO Pharma (NASDAQ:SILO) - Vimarsana News

Silo Pharma Collaborates With Medspray Pharma For Intranasal Technology For Stress Disorder Candidate - SILO Pharma (NASDAQ:SILO)

Silo Pharma Inc (NASDAQ: SILO) announced a new exclusive license agreement with Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for Silo's intranasal therapeutic drug SPC-15.

New ETF Tracks Developers of Obesity Drugs Amid Ozempic Hype - Vimarsana News

New ETF Tracks Developers of Obesity Drugs Amid Ozempic Hype

The Tema Cardiovascular and Metabolic ETF (HRTS) tracks companies involved in the treatment of cardio-metabolic diseases.

Denali Therapeutics (NASDAQ:DNLI) and Cortexyme (NASDAQ:CRTX) Head-To-Head Review - Vimarsana News

Denali Therapeutics (NASDAQ:DNLI) and Cortexyme (NASDAQ:CRTX) Head-To-Head Review

Denali Therapeutics (NASDAQ:DNLI – Get Free Report) and Cortexyme (NASDAQ:CRTX – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends. Profitability This table compares Denali Therapeutics and Cortexyme’s net […]

Source: wkrb13.com
FSD Pharma Provides Update on Proposed Dividend Distribution for Shareholders of FSD Pharma to Receive Shares of Celly Nutrition on a One for One Basis - Vimarsana News

FSD Pharma Provides Update on Proposed Dividend Distribution for Shareholders of FSD Pharma to Receive Shares of Celly Nutrition on a One for One Basis

BioPharma

Astellas Pharma (OTCMKTS:ALPMY) Reaches New 1-Year Low at $11.25 - Vimarsana News

Astellas Pharma (OTCMKTS:ALPMY) Reaches New 1-Year Low at $11.25

Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) shares reached a new 52-week low on Monday . The stock traded as low as $11.25 and last traded at $11.57, with a volume of 586209 shares trading hands. The stock had previously closed at $11.78. Analysts Set New Price Targets Separately, Jefferies Financial Group cut Astellas […]